Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial-Reference-Cited by-同舟云学术

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Published:2015-08 Issue:8 Volume:16 Page:908-918
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Ribas Antoni,Puzanov Igor,Dummer Reinhard,Schadendorf Dirk,Hamid Omid,Robert Caroline,Hodi F Stephen,Schachter Jacob,Pavlick Anna C,Lewis Karl D,Cranmer Lee D,Blank Christian U,O'Day Steven J,Ascierto Paolo A,Salama April K S,Margolin Kim A,Loquai Carmen,Eigentler Thomas K,Gangadhar Tara C,Carlino Matteo S,Agarwala Sanjiv S,Moschos Stergios J,Sosman Jeffrey A,Goldinger Simone M,Shapira-Frommer Ronnie,Gonzalez Rene,Kirkwood John M,Wolchok Jedd D,Eggermont Alexander,Li Xiaoyun Nicole,Zhou Wei,Zernhelt Adriane M,Lis Joy,Ebbinghaus Scot,Kang S Peter,Daud Adil

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Targeting oncogenic drivers and the immune system in melanoma;McArthur;J Clin Oncol,2013

2. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

3. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma;Robert;N Engl J Med,2011

4. The role of BRAF V600 mutation in melanoma;Ascierto;J Transl Med,2012

5. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012

Cited by 1382 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging Immune Checkpoint Inhibitors for the Treatment of Oropharyngeal Squamous Cell Carcinoma;Oral Oncology Reports;2024-09

2. The roles of migrasomes in immunity, barriers, and diseases;Acta Biomaterialia;2024-09

3. Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis;Investigational New Drugs;2024-08-14

4. A viable remedy for overcoming resistance to anti-PD-1 immunotherapy: Fecal microbiota transplantation;Critical Reviews in Oncology/Hematology;2024-08

5. Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma;International Immunopharmacology;2024-08